Civitas Therapeutics Inc. announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research for its lead drug candidate for Parkinson’s disease,CVT-301, an inhaled formulation of levodopa (L-dopa).
The grant will support the clinical development of CVT-301, which has the potential to produce relief from debilitating motor fluctuations associated with Parkinson’s disease.
Civitas has conducted a range of preclinical studies demonstrating CVT-301’s ability to deliver consistent systemic exposure of L-dopa compared to oral administration. CVT-301 was also shown to achieve durable motor function restoration in animal models of Parkinson’s disease in comparative studies with oral L-dopa, providing evidence that CVT-301 has the potential to address motor fluctuations in patients.
The grant provides support for CVT-301 clinical studies through proof-of-concept, which is anticipated to be complete by the end of 2012. Clinical trials of CVT-301 are planned to begin in 2011.
Release Date: Nov. 29, 2011
Source: Civitas Therapeutics Inc.